1

2

3

4

5

6

8

9

10

11

12

13

14

15

16

17

18

19

2021

22

23

24

25

2627

Empagliflozin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial Running title: Empagliflozin for COVID-19 **RECOVERY Collaborative Group*** *The writing committee and trial steering committee are listed at the end of this manuscript and a complete list of collaborators in the Randomised Evaluation of COVID-19 Therapy (RECOVERY) trial is provided in the Supplementary Appendix. Correspondence to: Prof Peter W Horby and Prof Martin J Landray, RECOVERY Central Coordinating Office, Richard Doll Building, Old Road Campus, Roosevelt Drive, Oxford OX3 7LF, United Kingdom. Email: recoverytrial@ndph.ox.ac.uk Word count: Abstract – 255 words Main text – 2846 words References – 25 Tables & Figures – 2+3

SUMMARY

28

49

29 Background: Empagliflozin has been proposed as a treatment for COVID-19 on the 30 basis of its anti-inflammatory, metabolic and haemodynamic effects. **Methods:** In this randomised, controlled, open-label trial, several possible treatments are 31 32 compared with usual care in patients hospitalised with COVID-19. Eligible and consenting 33 adults were randomly allocated in a 1:1 ratio to either usual standard of care alone or 34 usual standard of care plus empagliflozin 10mg once daily for 28 days or until discharge 35 using web-based simple (unstratified) randomisation with allocation concealment. The 36 primary outcome was 28-day mortality. On 3 March the independent data monitoring 37 committee recommended that the investigators review the data and recruitment was 38 consequently stopped on 7 March. The trial is registered with ISRCTN (50189673) and 39 clinicaltrials.gov (NCT04381936). 40 Findings: Between 8 July 2021 and 6 March 2023, 4271 patients were randomly 41 allocated to receive either empagliflozin (2113 patients) or usual care alone (2158 42 patients). Overall, 289 (14%) patients allocated to empagliflozin and 307 (14%) patients 43 allocated to usual care died within 28 days (rate ratio 0.96; 95% confidence interval [CI] 44 0.82-1.13: p=0.64). There was no evidence of significant differences in duration of 45 hospitalisation (median 8 days vs. 8 days) or the proportion of patients discharged from hospital alive within 28 days (79% vs. 78%; rate ratio 1.03; 95% CI 0.96-1.10; p=0.44). 46 47 Among those not on invasive mechanical ventilation at baseline, there was no evidence 48 of a significant difference in the proportion meeting the composite endpoint of invasive

mechanical ventilation or death (16% vs. 17%; risk ratio 0.95; 95% CI 0.84-1.08; p=0.44).

- 50 Interpretation: In adults hospitalised with COVID-19, empagliflozin was not associated
- with reductions in 28-day mortality, duration of hospital stay, or risk of progressing to
- 52 invasive mechanical ventilation or death.
- 53 **Funding:** UK Research and Innovation (Medical Research Council) and National Institute
- of Health Research (Grant ref: MC_PC_19056), and Wellcome Trust (Grant Ref:
- 55 222406/Z/20/Z).

- Trial registration: ClinicalTrials.gov NCT04381936
- 57 https://clinicaltrials.gov/ct2/show/NCT04381936
- 58 ISRCTN50189673 http://www.isrctn.com/ISRCTN50189673
- 59 **Keywords:** COVID-19, empagliflozin, clinical trial.

INTRODUCTION

61

62

63

64

65

66

67

68

69

70

71

72

73

74

75

76

77

78

79

80

81

82

Patients with cardiometabolic diseases (such as heart failure, diabetes and chronic kidney disease) are at increased risk of hospitalization and death from COVID-19. Sodium glucose co-transporter 2 inhibitors (SGLT2i) have been shown to reduce cardiovascular and kidney events in patients with cardiometabolic diseases. The precise mechanisms of such benefit are not known, but SGLT2i appear to favourably modify some pathways that are dysregulated in acute illnesses like COVID-19. Inflammation is a key feature of severe COVID-19. Markedly raised levels of inflammatory markers such as C-reactive protein, ferritin, interleukin-6 (IL-6) and other cytokines are observed in severe cases and are associated with poor outcomes.^{2,3} Corticosteroids, IL-6 inhibitors and Janus kinase (JAK) inhibitors have been shown to reduce mortality in patients with severe COVID-19.4-6 Together these results show that inflammation is modifiable and anti-inflammatory therapy can improve clinical outcomes. SGLT2i can reduce inflammation, ^{7,8} including via attenuation of the nucleotide binding domain (NOD)like pyrin domain 3 (NLRP3) inflammasome, which correlates with disease severity in COVID-19.9,10 A meta-analysis of 26 trials in patients with type 2 diabetes mellitus showed a reduced risk of pneumonia and septic shock among patients allocated SGLT2i.11 In addition, SGLT2i inhibit glycolysis and stimulate lipolysis which may create a less favourable energetic environment for viruses like COVID-19,12-14 and improve endothelial function.¹⁵ The DARE-19 trial compared dapagliflozin 10mg once daily with placebo in 1250 patients hospitalised with COVID-19 who had at least one cardiometabolic risk factor but were not

critically ill.¹⁶ The primary outcome of new or worsened organ dysfunction or death occurred in 70 (11%) of the dapaglifozin group versus 86 (14%) in the placebo group (hazard ratio [HR] 0.80, 95% CI 0.58-1.10). The dual primary outcome of improvement in clinical status by day 30 was also not significantly affected (win ratio 1.09, 95% CI 0.97-1.22). Dapagliflozin was well-tolerated and appeared safe (with fewer serious adverse events reported in the dapaglifozin group compared to placebo). Here we report the results of a large randomised controlled trial of empagliflozin in patients hospitalised with COVID-19.

METHODS

Study design and participants

The Randomised Evaluation of COVID-19 therapy (RECOVERY) trial is an investigator-initiated, individually randomised, controlled, open-label, adaptive platform trial to evaluate the effects of potential treatments in patients hospitalised with COVID-19. Details of the trial design and results for other possible treatments (dexamethasone, hydroxychloroquine, lopinavir-ritonavir, azithromycin, tocilizumab, convalescent plasma, colchicine, aspirin, casirivimab plus imdevimab, baricitinib, and high-dose corticosteroids in hypoxic patients not requiring ventilatory support) have been published previously. ^{6,17}
The trial is underway at hospital organisations in the United Kingdom supported by the National Institute for Health and Care Research Clinical Research Network, as well as in South and Southeast Asia and Africa. Of these, 118 hospitals in the UK, 5 in Nepal, 4 in Indonesia, 2 in Vietnam, 4 in South Africa, 1 in Ghana and 5 in India enrolled participants in the evaluation of empagliflozin (appendix pp 2-31). The trial is coordinated by the

Nuffield Department of Population Health at University of Oxford (Oxford, UK), the trial sponsor. The trial is conducted in accordance with the principles of the International Conference on Harmonisation—Good Clinical Practice guidelines and approved by the UK Medicines and Healthcare products Regulatory Agency (MHRA) and the Cambridge East Research Ethics Committee (ref: 20/EE/0101). The protocol, statistical analysis plan, and additional information are available on the study website www.recoverytrial.net.

Patients admitted to hospital were eligible for the study if they had clinically suspected or laboratory confirmed SARS-CoV-2 infection and no medical history that might, in the opinion of the attending clinician, put the patient at significant risk if they were to participate in the trial. Children (age <18 years) and pregnant women were not eligible for randomisation due to limited data on use of empagliflozin in these groups such that it was not possible to make an evidence-based benefit-risk assessment. Patients with type 1 diabetes mellitus (or post-pancreatectomy diabetes), a history of ketoacidosis or type 2 diabetes mellitus with ketosis at the time of recruitment were ineligible for the comparison of empagliflozin vs. usual care (further details in appendix pp 32-33). Written informed consent was obtained from all patients, or a legal representative if patients were too unwell or unable to provide consent.

Randomisation and masking

Baseline data were collected using a web-based case report form that included demographics, level of respiratory support, major comorbidities, suitability of the study treatment for a particular patient, SARS-CoV-2 vaccination status, and treatment availability at the study site (appendix pp 43-45). For some patients, empagliflozin was

unavailable at the hospital at the time of enrolment or was considered by the managing physician to be either definitely indicated or definitely contraindicated. These patients were excluded from the randomised comparison between empagliflozin and usual care. Eligible and consenting adult patients were assigned in a 1:1 ratio to either usual standard of care or usual standard of care plus empagliflozin using web-based simple (unstratified) randomisation with allocation concealed until after randomisation (appendix pp 41-43). Patients allocated to empagliflozin were to receive 10mg orally daily for 28 days in total or until discharge, whichever occurred earlier. Investigators were instructed how to identify and manage ketosis that may develop during treatment with empagliflozin (appendix p 32-33). As a platform trial, and in a factorial design, patients could be simultaneously randomised to other treatment groups: i) baricitinib versus usual care, ii) higher-dose corticosteroids versus usual care, iii) sotrovimab versus usual care, iv) molnupiravir versus usual care, and v) nirmatrelvir-ritonavir versus usual care (appendix pp 41-42). Participants and local study staff were not masked to the allocated treatment. Other than members of the Data Monitoring Committee, all individuals involved in the trial were masked to aggregated outcome data while recruitment and 28-day follow-up were ongoing.

Procedures

127

128

129

130

131

132

133

134

135

136

137

138

139

140

141

142

143

144

145

146

147

148

A single online follow-up form was completed when participants were discharged, had died or at 28 days after randomisation, whichever occurred earliest (appendix pp 47-55). Information was recorded on adherence to allocated study treatment, receipt of other

COVID-19 treatments, duration of admission, receipt of respiratory or renal support, and vital status (including cause of death). In addition, in the UK, routine healthcare and registry data were obtained including information on vital status (with date and cause of death), discharge from hospital, receipt of respiratory support, or renal replacement therapy. For sites outside the UK a further case report form (appendix pp 56-57) collected vital status at day 28 (if not already reported on follow-up form).

Outcomes

Outcomes were assessed at 28 days after randomisation, with further analyses specified at 6 months. The primary outcome was all-cause mortality at 28 days. Secondary outcomes were time to discharge from hospital, and, among patients not on invasive mechanical ventilation at randomisation, invasive mechanical ventilation (including extracorporal membrane oxygenation) or death. Prespecified subsidiary clinical outcomes were use of non-invasive respiratory support, time to successful cessation of invasive mechanical ventilation (defined as cessation of invasive mechanical ventilation within, and survival to, 28 days), use of renal dialysis or haemofiltration, cause-specific mortality, bleeding events, thrombotic events, major cardiac arrhythmias, thrombotic and bleeding events, other infections and metabolic complications (including ketoacidosis). Information on suspected serious adverse reactions was collected in an expedited fashion to comply with regulatory requirements.

Sample size and role of the independent Data Monitoring Committee

The intention for this comparison was to continue recruitment until sufficient primary outcomes had accrued to have 90% power to detect a proportional risk reduction of 20% at a two-sided significance level of 0.01. The independent Data Monitoring Committee reviewed unblinded analyses of the study data and any other information considered relevant to the trial at intervals of around 2-3 months (depending on speed of enrolment) and was charged with determining if, in their view, the randomised comparisons in the study provided evidence on mortality that was strong enough (with a range of uncertainty around the results that was narrow enough) to affect national and global treatment strategies (appendix p 58). On 3 March 2023, the Data Monitoring Committee recommended that the investigators review the unblinded data from the empagliflozin comparison (appendix p 59). Consequently, recruitment to the empagliflozin comparison was closed on 7 March 2023. **Statistical Analysis**

170

171

172

173

174

175

176

177

178

179

180

181

182

183

184

185

186

187

188

189

190

The primary analysis for all outcomes was by intention-to-treat comparing patients randomised to empagliflozin with patients randomised to usual care but for whom empagliflozin was both available and suitable as a treatment. For the primary outcome of 28-day mortality, the hazard ratio from an age- and respiratory status-adjusted Cox model was used to estimate the mortality rate ratio. We constructed Kaplan-Meier survival curves to display cumulative mortality over the 28-day period. We used the same Cox regression method to analyse time to hospital discharge and successful cessation of

invasive mechanical ventilation, with patients who died in hospital right-censored on day 29. Median time to discharge was derived from Kaplan-Meier estimates. For the prespecified composite secondary outcome of progression to invasive mechanical ventilation or death within 28 days (among those not receiving invasive mechanical ventilation at randomisation), and the subsidiary clinical outcomes of receipt of ventilation and use of haemodialysis or haemofiltration, the precise dates were not available and so a logbinomial regression model was used to estimate the risk ratio adjusted for age and respiratory status. Prespecified subgroup analyses were performed for the primary outcome using the statistical test of interaction (test for heterogeneity or trend), in accordance with the prespecified analysis plan, defined by the following characteristics at randomisation: age, sex, ethnicity, level of respiratory support, days since symptom onset, and use of corticosteroids (appendix p 139). Estimates of rate and risk ratios are shown with 95% confidence intervals. All p-values are 2-sided and are shown without adjustment for multiple testing. The full database is held by the study team which collected the data from study sites and performed the analyses at the Nuffield Department of Population Health, University of Oxford (Oxford, UK). Analyses were performed using SAS version 9.4 and R version 3.4. The trial is registered with ISRCTN (50189673) and clinicaltrials.gov (NCT04381936).

Role of the funding source

191

192

193

194

195

196

197

198

199

200

201

202

203

204

205

206

207

208

209

210

Neither the funders of the study nor Boehringer Ingelheim, which supplied empagliflozin for sites outside the UK, had any role in study design, data collection, data analysis, data interpretation, or writing of the report. The corresponding authors had full access to all the data in the study and had final responsibility for the decision to submit for publication.

RESULTS

212

213

214

215

216

217

218

219

220

221

222

223

224

225

226

227

228

229

230

231

232

233

Between 8 July 2021 and 6 March 2023, 4271 (74%) of 5740 patients enrolled into the RECOVERY trial were eligible to be randomly allocated to empagliflozin (i.e. empagliflozin was available in the hospital at the time and the attending clinician was of the opinion that the patient had no known indication for or contraindication to empagliflozin, figure 1). The characteristics of the 1469 patients enrolled into the RECOVERY trial during this period but not included in the empadiflozin comparison are shown in webtable 1. 2113 patients were randomly allocated to empagliflozin and 2158 were randomly allocated to usual care. The mean age of study participants in this comparison was 61.5 years (SD 16.4) and the median time since symptom onset was 8 days (IQR 5 to 11 days). At randomisation, 3842 (90%) patients were receiving corticosteroids, about one-quarter were receiving remdesivir and about one-quarter had received tocilizumab (table 1). The follow-up form was completed for 2089 (99%) patients in the empagliflozin group and 2138 (99%) patients in the usual care group. Among patients with a completed follow-up form, 1889 (90%) allocated to empagliflozin received at least one dose and, of these, 1321 (70%) received it on most (≥90%) days of their admission (or until 28 days after

234

235

236

237

238

239

240

241

242

243

244

245

246

247

248

249

250

251

252

253

254

255

randomisation if not discharged sooner) (figure 1; webtable 2). By comparison, <1% of those allocated to usual care alone received any dose of empagliflozin. Use of other treatments for COVID-19 was similar among patients allocated empagliflozin and among those allocated usual care (webtable 2). Primary and secondary outcome data are known for >99% of randomly assigned patients. There was no evidence of a significant difference in the proportion of patients who met the primary outcome of 28-day mortality between the two randomised groups (289 [14%] patients in the empagliflozin group vs. 307 [14%] patients in the usual care group; hazard ratio 0.96; 95% confidence interval [CI], 0.82-1.13; p=0.64; figure 2). We observed similar results across all pre-specified sub-groups (figure 3), except among the small group of patients not requiring oxygen at baseline or not receiving corticosteroids among whom there were very few (about 20) events. The median time to discharge from hospital alive was 8 days in both groups and there was no evidence of a significant difference in the probability of being discharged alive within 28 days (79 vs. 78%, rate ratio 1.03, 95% CI 0.96 to 1.10, p=0.44) (table 2). Among those not on invasive mechanical ventilation at baseline, the number of patients progressing to the pre-specified composite secondary outcome of invasive mechanical ventilation or death was similar in both groups (16% vs. 17%, risk ratio 0.95, 95% CI 0.84 to 1.08, p=0.44). Similar results were seen in all pre-specified subgroups of patients (webfigure 1, webfigure 2). We found no evidence of significant differences in the prespecified subsidiary clinical outcomes of cause-specific mortality (webtable 3), use of ventilation or successful

cessation of invasive mechanical ventilation (table 2). We found no evidence of a significant difference in the incidence of acute kidney injury (defined as an increase in the pre-randomisation creatinine concentration of at least 50%), or need for renal dialysis or haemofiltration (table 2, webtable 4). The incidence of new cardiac arrhythmias, bleeding events, and non-coronavirus infections was also similar in the two groups (webtable 4). There were fewer thrombotic events among patients allocated empagliflozin compared to placebo (2.5% vs. 3.9%, absolute difference -1.4% [-0.4 to -2.5]; webtable 4). The incidence of metabolic complications were similar in the two groups, with reported ketoacidosis in 5 vs. 2 patients. There were two reports of a serious adverse reaction believed to be related to empagliflozin: both were ketosis without acidosis (including one patient without diabetes) and resolved rapidly on cessation of the drug.

DISCUSSION

In this large, randomised trial involving over 4000 patients from 7 countries and nearly 600 deaths, allocation to empagliflozin was not associated with reductions in mortality, duration of hospitalisation, or the risk of being ventilated or dying for those not on ventilation at baseline. These results were consistent across prespecified subgroups of age, sex, race and duration of symptoms prior to randomisation.

The benefits of immunomodulatory therapies in patients with moderate to severe COVID-19 demonstrates the importance of inflammation in this patient group and empagliflozin was proposed as a treatment for COVID-19 partly based on its anti-inflammatory activity as well as purported benefits on endothelial function and cellular energy metabolism. The

278

279

280

281

282

283

284

285

286

287

288

289

290

291

292

293

294

295

296

297

298

299

lack of evidence of benefit from empagliflozin in this large well-powered trial suggests that these properties of empagliflozin are either insufficient to produce a meaningful reduction in mortality risk or are not affecting the relevant pathways in moderate to severe COVID-19. There is weak evidence that there may be some benefit on 28-day mortality in patients not receiving a corticosteroid or not requiring oxygen, which are largely the same patients. However, this observation is based on a very small number of events, marginally significant tests for heterogeneity or trend, and is not supported by either of the secondary outcomes. Only one other trial of an SGLT2i in COVID-19 has been reported to date. The DARE-19 trial recruited 1250 patients hospitalised (but not critically ill) with COVID-19 and with at least one cardiometabolic risk factor (i.e. hypertension, type 2 diabetes mellitus, atherosclerotic cardiovascular disease, heart failure or chronic kidney disease). 16 There was no significant effect of dapagliflozin on either of the two dual primary outcomes (new or worsened organ function or death, and change in clinical status by day 30), although there were numerically fewer poor outcomes in dapagliflozin group, including 41 deaths compared to 54 in the placebo group. However, DARE-19 was not large enough to detect plausibly moderate benefits of treatment. Meta-analysing the results on mortality from DARE-19 and RECOVERY yields a summary relative risk of 0.93 (0.80-1.08). Trials of SGLT2i in chronic disease setting have found consistent evidence of a reduction in acute kidney injury (AKI): a meta-analysis of 13 large placebo-controlled trials including over 2000 AKI events reported a reduction of nearly one-quarter (relative risk 0.77, 95% CI 0.70-0.84) in this outcome. The RECOVERY trial did not find evidence of benefit (or

300

301

302

303

304

305

306

307

308

309

310

311

312

313

314

315

316

317

318

319

320

321

harm) of empagliflozin on the risk of developing AKI in the acute setting where AKI may have already begun prior to randomisation. Strengths of this trial included that it was randomised, had a large sample size, broad eligibility criteria, was international and more than 99% of patients were followed up for the primary outcome. However, detailed information on laboratory markers of inflammation and immune response was not collected, nor was information on radiological or physiological outcomes. Although this randomised trial is open label (i.e., participants and local hospital staff are aware of the assigned treatment), the outcomes are unambiguous and were ascertained without bias through linkage to routine health records in the large majority of patients. The RECOVERY trial only studied patients who had been hospitalised with COVID-19 and, therefore, is not able to provide any evidence on the safety and efficacy of empagliflozin used in other patient groups. Due to the recommendation that empagliflozin be taken orally (and not via a gastric feeding tube), there were few patients recruited requiring invasive mechanical ventilation. Nevertheless, the reassuring safety findings in RECOVERY suggest that SGLT2i can be safely used in the acute setting and do not need to be routinely discontinued if there is an appropriate indication. These results show that the key risk of ketoacidosis can be safely mitigated with simple monitoring and advice to managing physicians. In summary, the results of this large, randomised trial do not support the use of empagliflozin as a treatment for adults hospitalised with COVID-19.

Contributors

This manuscript was initially drafted by the RH, PWH and MJL, further developed by the Writing Committee, and approved by all members of the trial steering committee. PWH and MJL vouch for the data and analyses, and for the fidelity of this report to the study protocol and data analysis plan. PWH, JKB, MB, MK, SNF, TJ, EJ, KJ, WSL, AMo, AMuk, AMum, JN, KR, GT, MM, RH, and MJL designed the trial and study protocol. MM, MC, G P-A, LP, RKJ, DG, JD, FH, AK, PT-T, JW, CG, PD, RS, the Data Linkage team at the RECOVERY Coordinating Centre, and the Health Records and Local Clinical Centre staff listed in the appendix collected the data. NS and JRE did the statistical analysis. All authors contributed to data interpretation and critical review and revision of the manuscript. PWH and MJL had access to the study data and had final responsibility for the decision to submit for publication.

335

336

337

338

339

340

341

342

343

344

345

346

347

348

349

350

351

352

353

354

355

Data sharing

Writing Committee (on behalf of the RECOVERY Collaborative Group): Peter W Horby, Natalie Staplin, Leon Peto, Jonathan R Emberson, Mark Campbell, Guilherme Pessoa-Amorim, Buddha Basnyat, Louise Thwaites, Rogier van Doorn, Raph L Hamers, Jeremy Nel, John Amuasi, Roshan Kumar Jha, Dipansu Ghosh, Jonathan Douse, Fergus Hamilton, Anthony Kerry, Pinky Thu-Ta, John Widdrington, Christopher A Green, Purav Desai, Richard Stewart, Nguyen Thanh Phong, J Kenneth Baillie, Maya Buch, Saul N Faust, Thomas Jaki, Edmund Juszczak, Katie Jeffery, Marian Knight, Wei Shen Lim, Alan Montgomery, Aparna Mukherjee, Andrew Mumford, Kathryn Rowan, Guy Thwaites, Marion Mafham, Richard Haynes, Martin J Landray. **Data Monitoring Committee** Peter Sandercock, Janet Darbyshire, David DeMets, Robert Fowler, David Lalloo, Mohammed Munavvar, Janet Wittes. **Declaration of interests** The authors have no conflict of interest or financial relationships relevant to the submitted work to disclose. No form of payment was given to anyone to produce the manuscript. All authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. The Nuffield Department of Population Health at the University of Oxford has a staff policy of not accepting honoraria or consultancy fees directly or indirectly from industry (see https://www.ndph.ox.ac.uk/files/about/ndph-independenceof-research-policy-jun-20.pdf).

The protocol, consent form, statistical analysis plan, definition & derivation of clinical characteristics & outcomes, training materials, regulatory documents, and other relevant study materials are available online at www.recoverytrial.net. As described in the protocol, the Trial Steering Committee will facilitate the use of the study data and approval will not be unreasonably withheld. Deidentified participant data will be made available to bona fide researchers registered with an appropriate institution within 3 months of publication. However, the Steering Committee will need to be satisfied that any proposed publication is of high quality, honours the commitments made to the study participants in the consent documentation and ethical approvals, and is compliant with relevant legal and regulatory requirements (e.g. relating to data protection and privacy). The Steering Committee will have the right to review and comment on any draft manuscripts prior to publication. Data will be made available in line with the policy and procedures described at: https://www.ndph.ox.ac.uk/data-access. Those wishing to request access should complete the form at https://www.ndph.ox.ac.uk/files/about/data access enquiry form 13 6 2019.docx and e-mailed to: data.access@ndph.ox.ac.uk

Acknowledgements

356

357

358

359

360

361

362

363

364

365

366

367

368

369

370

371

372

373

374

375

376

377

378

Above all, we would like to thank the thousands of patients who participated in this trial. We would also like to thank the many doctors, nurses, pharmacists, other allied health professionals, and research administrators at NHS hospital organisations across the whole of the UK, supported by staff at the National Institute of Health Research (NIHR) Clinical Research Network, NHS DigiTrials, Public Health England, Department of Health

& Social Care, the Intensive Care National Audit & Research Centre, Public Health Scotland, National Records Service of Scotland, the Secure Anonymised Information Linkage (SAIL) at University of Swansea, and the NHS in England, Scotland, Wales and Northern Ireland. The RECOVERY trial is supported by grants to the University of Oxford from UK Research and Innovation (UKRI) and NIHR (MC_PC_19056), the Wellcome Trust (Grant Ref: 222406/Z/20/Z) through the COVID-19 Therapeutics Accelerator, and by core funding provided by the NIHR Oxford Biomedical Research Centre, the Wellcome Trust, the Bill and Melinda Gates Foundation, the Foreign, Commonwealth and Development Office, Health Data Research UK, the Medical Research Council Population Health Research Unit, the NIHR Health Protection Unit in Emerging and Zoonotic Infections, and NIHR Clinical Trials Unit Support Funding. TJ is supported by a grant from UK Medical Research Council (MC UU 0002/14). WSL is supported by core funding provided by NIHR Nottingham Biomedical Research Centre. Boehringer-Ingelheim supplied empagliflozin free of charge for use in this trial in countries outside the UK. Boehringer Ingelheim was given the opportunity to review the manuscript for medical and scientific consistency as it relates to Boehringer Ingelheim substances, as well as intellectual property considerations. The views expressed in this publication are those of the authors and not necessarily those of the NHS, the NIHR, or the UK Department of Health and Social Care.

Conflicts of interest

379

380

381

382

383

384

385

386

387

388

389

390

391

392

393

394

395

396

397

398

RH and MJL are named on grants to the University of Oxford from Boehringer-Ingelheim for other research projects. No form of payment was given to anyone to produce the manuscript. All authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. The Nuffield Department of Population Health at the University of Oxford has a staff policy of not accepting honoraria or consultancy fees directly or indirectly from industry (see https://www.ndph.ox.ac.uk/files/about/ndph-independence-of-research-policy-jun-20.pdf).

References

- 409 1. Nuffield Department of Population Health Renal Studies Group and the SGLT2
- inhibitor Meta-Analysis Cardio-Renal Trialists' Consortium. Impact of diabetes on the
- 411 effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative
- 412 meta-analysis of large placebo-controlled trials. *Lancet*. Nov 19 2022;400(10365):1788-
- 413 1801. doi:10.1016/S0140-6736(22)02074-8
- 414 2. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019
- 415 novel coronavirus in Wuhan, China. *Lancet*. Feb 15 2020;395(10223):497-506.
- 416 doi:10.1016/S0140-6736(20)30183-5
- 417 3. Wang JH, Chen RD, Yang HK, et al. Inflammation-associated factors for
- 418 predicting in-hospital mortality in patients with COVID-19. *J Med Virol*. May
- 419 2021;93(5):2908-2917. doi:10.1002/jmv.26771
- 420 4. W. H. O. Rapid Evidence Appraisal for COVID-19 Therapies Working Group,
- 421 Sterne JAC, Murthy S, et al. Association Between Administration of Systemic
- 422 Corticosteroids and Mortality Among Critically III Patients With COVID-19: A Meta-
- 423 analysis. *Jama*. Oct 6 2020;324(13):1330-1341. doi:10.1001/jama.2020.17023
- 424 5. Group WHOREAfC-TW, Shankar-Hari M, Vale CL, et al. Association Between
- 425 Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for
- 426 COVID-19: A Meta-analysis. *Jama*. Aug 10 2021;326(6):499-518.
- 427 doi:10.1001/jama.2021.11330
- 428 6. Group RC. Baricitinib in patients admitted to hospital with COVID-19
- 429 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-
- 430 analysis. *Lancet*. Jul 30 2022;400(10349):359-368. doi:10.1016/S0140-6736(22)01109-
- 431 6
- 432 7. Maayah ZH, Ferdaoussi M, Takahara S, Soni S, Dyck JRB. Empagliflozin
- 433 suppresses inflammation and protects against acute septic renal injury.
- 434 Inflammopharmacology. Feb 2021;29(1):269-279. doi:10.1007/s10787-020-00732-4
- 435 8. Bonnet F, Scheen AJ. Effects of SGLT2 inhibitors on systemic and tissue low-
- 436 grade inflammation: The potential contribution to diabetes complications and
- cardiovascular disease. *Diabetes & metabolism*. Dec 2018;44(6):457-464.
- 438 doi:10.1016/j.diabet.2018.09.005
- 439 9. Rodrigues TS, Keyla SG, Ishimoto AY, et al. Inflammasome activation in COVID-
- 440 19 patients. *medRxiv*. 2020;doi:https://doi.org/10.1101/2020.08.05.20168872
- 441 10. Kim SR, Lee SG, Kim SH, et al. SGLT2 inhibition modulates NLRP3
- inflammasome activity via ketones and insulin in diabetes with cardiovascular disease.
- 443 Nat Commun. May 1 2020;11(1):2127. doi:10.1038/s41467-020-15983-6

- 444 11. Li H-L, Tse Y-K, Chandramouli C, et al. Sodium-Glucose Cotransporter 2
- Inhibitors and the Risk of Pneumonia and Septic Shock. *The Journal of Clinical*
- 446 Endocrinology & Metabolism. 2022;107(12):3442-3451. doi:10.1210/clinem/dgac558
- 12. Daniele G, Xiong J, Solis-Herrera C, et al. Dapagliflozin Enhances Fat Oxidation
- 448 and Ketone Production in Patients With Type 2 Diabetes. *Diabetes care*. Nov
- 449 2016;39(11):2036-2041. doi:10.2337/dc15-2688
- 450 13. Icard P, Lincet H, Wu Z, et al. The key role of Warburg effect in SARS-CoV-2
- replication and associated inflammatory response. *Biochimie*. Jan 2021;180:169-177.
- 452 doi:10.1016/j.biochi.2020.11.010
- 453 14. Codo AC, Davanzo GG, Monteiro LB, et al. Elevated Glucose Levels Favor
- 454 SARS-CoV-2 Infection and Monocyte Response through a HIF-1α/Glycolysis-
- 455 Dependent Axis. *Cell Metab.* Sep 1 2020;32(3):437-446.e5.
- 456 doi:10.1016/j.cmet.2020.07.007
- 457 15. Solini A, Giannini L, Seghieri M, et al. Dapagliflozin acutely improves endothelial
- dysfunction, reduces a ortic stiffness and renal resistive index in type 2 diabetic patients:
- 459 a pilot study. Cardiovasc Diabetol. Oct 23 2017;16(1):138. doi:10.1186/s12933-017-
- 460 0621-8
- 461 16. Kosiborod MN, Esterline R, Furtado RHM, et al. Dapagliflozin in patients with
- cardiometabolic risk factors hospitalised with COVID-19 (DARE-19): a randomised,
- double-blind, placebo-controlled, phase 3 trial. Lancet Diabetes Endocrinol. Sep
- 464 2021;9(9):586-594. doi:10.1016/S2213-8587(21)00180-7
- 17. RECOVERY Collaborative Group, Horby P, Lim WS, et al. Dexamethasone in
- Hospitalized Patients with Covid-19. *N Engl J Med*. Feb 25 2021;384(8):693-704.
- 467 doi:10.1056/NEJMoa2021436
- 468 18. RECOVERY Collaborative Group, Horby P, Mafham M, et al. Effect of
- 469 Hydroxychloroguine in Hospitalized Patients with Covid-19. *N Engl J Med.* Nov 19
- 470 2020;383(21):2030-2040. doi:10.1056/NEJMoa2022926
- 471 19. RECOVERY Collaborative Group, Horby PW, Mafham M, et al. Lopinavir-
- 472 ritonavir in patients admitted to hospital with COVID-19 (RECOVERY): a randomised,
- 473 controlled, open-label, platform trial. *Lancet*. Oct 5 2020;396(10259):1345-52.
- 474 doi:10.1016/S0140-6736(20)32013-4
- 475 20. RECOVERY Collaborative Group. Azithromycin in patients admitted to hospital
- with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.
- 477 Lancet. Feb 13 2021;397(10274):605-612. doi:10.1016/S0140-6736(21)00149-5
- 478 21. RECOVERY Collaborative Group. Tocilizumab in patients admitted to hospital
- with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.
- 480 Lancet. May 1 2021;397(10285):1637-1645. doi:10.1016/S0140-6736(21)00676-0

- 481 22. RECOVERY Collaborative Group, Horby PW, Estcourt L, et al. Convalescent
- plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised,
- 483 controlled, open-label, platform trial. *medRxiv*. 2021:2021.03.09.21252736.
- 484 doi:10.1101/2021.03.09.21252736

498

- 485 23. Group RC. Colchicine in patients admitted to hospital with COVID-19
- 486 (RECOVERY): a randomised, controlled, open-label, platform trial. *Lancet Respir Med*.
- 487 Dec 2021;9(12):1419-1426. doi:10.1016/S2213-2600(21)00435-5
- 488 24. Group RC. Aspirin in patients admitted to hospital with COVID-19 (RECOVERY):
- a randomised, controlled, open-label, platform trial. *Lancet*. Jan 8 2022;399(10320):143-
- 490 151. doi:10.1016/S0140-6736(21)01825-0
- 491 25. Group RC. Casirivimab and imdevimab in patients admitted to hospital with
- 492 COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. *Lancet*.
- 493 Feb 12 2022;399(10325):665-676. doi:10.1016/S0140-6736(22)00163-5
- 494 26. RECOVERY Collaborative Group. Higher dose corticosteroids in hospitalised
- 495 COVID-19 patients with hypoxia but not requiring ventilatory support (RECOVERY): a
- 496 randomised, controlled, open-label, platform trial. *MedRxiv*.
- 497 2023;doi:https://doi.org/10.1101/2022.12.16.22283578

Table 1: Baseline characteristics

	Treatment	allocation
	Empagliflozin (n=2113)	Usual care (n=2158)
Age, years	61.1 (16.3)	61.8 (16.4)
<70	1412 (67%)	1393 (65%)
≥70 to <80	434 (21%)	479 (22%)
≥80	267 (13%)	286 (13%)
Sex	207 (1370)	200 (1370)
Male	1326 (63%)	1339 (62%)
Female*	787 (37%)	819 (38%)
Country	101 (31 70)	019 (3070)
Ghana	2 (<0.5%)	2 (<0.5%)
India	24 (1%)	19 (1%)
Indonesia	68 (3%)	68 (3%)
		, ,
Nepal South Africa	139 (7%)	119 (6%)
South Africa	10 (<0.5%)	14 (1%)
Vietnam UK	40 (2%)	53 (2%)
	1830 (87%)	1883 (87%)
Race	4557 (740/)	1607 (740/)
White	1557 (74%)	1607 (74%)
Black, Asian, and minority ethnic	361 (17%)	330 (15%)
Unknown	195 (9%)	221 (10%)
lumber of days since symptom onset	8 (5-11)	8 (5-12)
lumber of days since hospitalisation	2 (1-3)	2 (1-3)
Respiratory support received	255 (420/)	200 (420()
None	255 (12%)	260 (12%)
Simple oxygen	1317 (62%)	1383 (64%)
Non invasive ventilation	512 (24%)	500 (23%)
Invasive mechanical ventilation	29 (1%)	15 (1%)
liochemistry	00 (00 440)	05 (00 454)
C-reactive protein, mg/L	83 (39-148)	85 (38-151)
Creatinine, umol/L	75 (62-94)	78 (63-96)
revious diseases	000 (400()	050 (400()
Diabetes	333 (16%)	356 (16%)
Heart disease	471 (22%)	455 (21%)
Chronic lung disease	533 (25%)	508 (24%)
Tuberculosis	9 (<0.5%)	7 (<0.5%)
HIV	21 (1%)	13 (1%)
Severe liver disease†	20 (1%)	21 (1%)
Severe kidney impairment‡	66 (3%)	80 (4%)
Any of the above	1014 (48%)	1039 (48%)
ARS-CoV-2 PCR test result	00.45 (5-54)	000= (0==:)
Positive	2046 (97%)	2097 (97%)
Negative	12 (1%)	10 (<0.5%)
Unknown	55 (3%)	51 (2%)
eceived a COVID-19 vaccine	1412 (67%)	1453 (67%)
se of other treatments		
Corticosteroids	1910 (90%)	1932 (90%)
Remdesivir	541 (26%)	547 (25%)
Tocilizumab	504 (24%)	491 (23%)
Plan to use tocilizumab within the next 24 hours	208 (10%)	240 (11%)

	Treatment allocation	
	Empagliflozin (n=2113)	Usual care (n=2158)
Other randomly assigned treatments		
Baricitinib	554 (26%)	591 (27%)
High dose steroids	160 (8%)	161 (7%)
Sotrovimab	185 (9%)	194 (9%)
Molnupiravir	143 (7%)	133 (6%)
Nirmatrelvir-ritonavir	19 (1%)	28 (1%)

Results are count (%), mean ± standard deviation, or median (inter-quartile range). *Includes 0 pregnant women. †Defined as requiring ongoing specialist care. ‡Defined as estimated glomerular filtration rate <30 mL/min/1.73m²

501

Table 2: Effect of allocation to empagliflozin on key study outcomes

	Treatment			
	Empagliflozin (n=2113)	Usual care (n=2158)	RR (95% CI)	p value
Primary outcome:				
28-day mortality	289 (14%)	307 (14%)	0.96 (0.82-1.13)	0.64
Secondary outcomes:				
Median time to being discharged alive, days	8 (5 to 19)	8 (5 to 20)		
Discharged from hospital within 28 days	1678 (79%)	1677 (78%)	1.03 (0.96-1.10)	0.44
Receipt of invasive mechanical ventilation or death*	338/2084 (16%)	371/2143 (17%)	0.95 (0.84-1.08)	0.44
Invasive mechanical ventilation	130/2084 (6%)	133/2143 (6%)	0.97 (0.77-1.21)	0.77
Death	274/2084 (13%)	302/2143 (14%)	0.96 (0.84-1.11)	0.59
Subsidiary clinical outcomes				
Receipt of ventilation†	245/1567 (16%)	259/1641 (16%)	1.00 (0.85-1.17)	0.97
Non-invasive ventilation	237/1572 (15%)	252/1643 (15%)	0.99 (0.84-1.16)	0.90
Invasive mechanical ventilation	51/1567 (3%)	49/1641 (3%)	1.09 (0.74-1.60)	0.66
Successful cessation of invasive mechanical ventilation	10/29 (35%)	6/15 (40%)	0.67 (0.24-1.85)	0.44
Renal replacement therapy§	45/2103 (2%)	44/2146 (2%)	0.96 (0.64-1.45)	0.86

RR=Rate Ratio for the outcomes of 28-day mortality and hospital discharge, and risk ratio for the outcome of receipt of invasive mechanical ventilation or death (and its subcomponents). Cl=confidence interval. *Analyses exclude those on invasive mechanical ventilation at randomization. ‡Analyses exclude those on any form of ventilation at randomisation. ‡Analyses restricted to those on invasive mechanical ventilation at randomisation. §Analyses exclude those on haemodialysis or haemofiltration at randomisation.

506

507

508

509

510

511

512

513

514

515

516

517

518

519

520

521

522

523

524


525

526

Figures Figure 1: Trial profile ITT=intention to treat. * Number recruited overall during period that adult participants could be recruited into empagliflozin comparison. Of the 4271 randomised to empagliflozin vs usual care, 1145 were additionally randomised to baricitinib vs usual care (554 [26%] of the empagliflozin group vs 591 [27%] of the usual care group); 321 were additionally randomised to higher-dose corticosteroids vs usual care (160 [8%] of the empagliflozin group vs 161 [7%] of the usual care group); 379 were additionally randomised to sotrovimab vs usual care (185 [9%] of the empagliflozin group vs 194 [9%] of the usual care group); 276 were additionally randomised to molnupiravir vs usual care (143 [7%] of the empagliflozin group vs 133 [6%] of the usual care group); and 47 patients were additionally randomised to nirmatrelvir-ritonavir vs usual care (19) [1%] of the empagliflozin group vs 28 [1%] of the usual care group). Figure 2: Effect of allocation to empagliflozin on 28-day mortality Figure 3: Effect of allocation to empagliflozin on 28-day mortality by baseline characteristics Subgroup-specific rate ratio estimates are represented by squares (with areas of the squares proportional to the amount of statistical information) and the lines through them correspond to the 95% CIs. The ethnicity, days since onset and use of corticosteroids subgroups exclude those with missing data, but these patients are included in the overall summary diamond.

Figure 1: Trial profile
medRxiv preprint doi: https://doi.org/10.1101/2023.04.13.23288469; this version posted April 19, 2023. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

It is made available under a CC-BY 4.0 International license.



ITT=intention to treat. *Number recruited overall during period that adult participants could be recruited into empagliflozin comparison.

Figure 2: Effect of allocation to empagliflozin on 28- day mortality medRxiv preprint doi: https://doi.org/10.1101/2023.04.13.23288499; this version posted April 19, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.




Figure 3: Effects of allocation to empagliflozin on 28- day mortality by baseline characteristics

	Empagliflozin	Usual care		RR (95% CI)			
Age, years (χ_1^2 =0.1; p=0.81)						
<70	123/1412 (9%)	115/1393 (8%)		1.01 (0.78- 1.30)			
≥70 <80	92/434 (21%)	113/479 (24%)		0.90 (0.68- 1.18)			
≥80	74/267 (28%)	79/286 (28%)		0.98 (0.71- 1.34)			
Sex (χ_1^2 =0.0; p=0.98)							
Men	189/1326 (14%)	205/1339 (15%)		0.96 (0.79- 1.18)			
Women	100/781 (13%)	102/817 (13%)		0.96 (0.73- 1.27)			
Race (χ_1^2 =1.0; p=0.33)							
White	240/1557 (15%)	257/1607 (16%)		0.98 (0.82- 1.17)			
BAME	30/361 (8%)	32/330 (10%)		0.75 (0.46- 1.24)			
Days since symptom onset	Days since symptom onset (χ^2_1 =0.0; p=0.91)						
≤7	146/1168 (12.5%)	162/1246 (13.0%)		0.96 (0.77- 1.21)			
>7	143/945 (15.1%)	145/912 (15.9%)		0.95 (0.75- 1.19)			
Respiratory support at rand	domization (χ^2_1 =4.7;	p=0.03)					
None	4/255 (2%)	18/260 (7%)	←—	0.24 (0.08- 0.70)			
Simple oxygen	142/1317 (11%)	162/1383 (12%)		0.92 (0.74- 1.16)			
Non invasive ventilation	128/512 (25%)	122/500 (24%)	- -	1.08 (0.84- 1.39)			
Invasive mechanical ventilation	on 15/29 (52%)	5/15 (33%)	-	> 1.68 (0.61-4.62)			
Use of corticosteroids (χ_1^2 =6.0; p=0.01)							
Yes	284/1910 (15%)	287/1932 (15%)		1.01 (0.86- 1.19)			
No	5/197 (3%)	19/218 (9%)	←	0.29 (0.11- 0.78)			
All participants	289/2113 (14%)	307/2158 (14%)		0.96 (0.82- 1.13) p=0.64			
			0.5 0.75 1 1.5	2			
			Empagliflozin Empagliflozi better worse	in			